IP Library › Granted Patent US 12,311,048
Granted Patent B2
US 12,311,048 · App. 17/289,468 · Granted May 27, 2025

Crosslinked materials

Inventors: Samir Mitragotri (Lexington, MA); Eric Spengler (Cambridge, MA); Douglas Levinson (Sherborn, MA); Douglas R. Vogus (Cambridge, MA)
Assignee: Fount Bio, Inc.
A61K8/735A61K8/44A61K8/49A61K8/8147A61K8/86A61Q19/00C08J3/24A61K2800/87A61K2800/91
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,311,048
App. No.
17/289,468
Granted
May 27, 2025
Kind
B2
Abstract

The present application describes to the synthesis, formulation and uses of crosslinkable entities and crosslinked materials.

Claims (13)

1. A method of improving a skin attribute, wherein the method comprises forming a composition at a site below the stratum corneum, wherein the composition comprises a first crosslinkable entity comprising a hyaluronic acid (HA) polymer conjugated to a first crosslink moiety via a linker, wherein the first crosslink moiety is a cyanobenzothiazole (CBT) crosslink moiety and the linker is glycine, wherein the method further comprises topical administration of the first crosslinkable entity to a skin site, which topical administration is carried out prior to, simultaneously, or after topical administration to the skin site of a second crosslinkable entity, wherein the second crosslinkable entity comprises at least one cysteine second crosslink moiety conjugated to a polymer, wherein the skin site is abraded before, after, or simultaneously with the topical administration of one or both of the first and second crosslinkable entities.

2. The method according to claim 1 , wherein the polymers of the first and second crosslinkable entities are the same.

3. The method according to claim 1 , wherein the polymer of the second crosslinkable entity is selected from the group consisting of PEG, PEG-diamine, polyacrylic acid, N-(2-Hydroxypropyl) methacrylamide (HPMA), polycaprolactone (PCL), and poly (lactic-co-glycolic acid) (PLGA).

4. The method according to claim 1 , wherein the at least one cysteine second crosslink moiety is independently selected from the group consisting of D-cysteine, and L-cysteine.

5. The method according to claim 1 , wherein the polymer of the second crosslinkable entity is, or comprises, a diamine, optionally wherein the diamine is ethylene diamine.

6. The method according to claim 1 , wherein the second crosslinkable entity is Cys-EDA-Cys.

7. The method according to claim 1 , wherein the skin attribute is selected from the group consisting of thickness, aesthetics, moisture content, smoothness, wrinkles, radiance, firmness, elasticity, atrophic skin, scars, fine line wrinkles, and skin translucency.

8. The method according to claim 1 , wherein the administration of the first and second crosslinkable entities is carried out simultaneously, optionally wherein the first and second crosslinkable entities are combined prior to administration, or as they are administered.

9. The method according to claim 1 , wherein the first and second crosslinkable entities are administered repeatedly.

10. The method according to claim 1 , wherein the skin site is abraded in that it is treated is by tape stripping, fraction laser treatment, or microneedling.

11. The method according to claim 10 , wherein the skin site is treated by microneedling.

12. The method according to claim 1 , wherein the skin site is abraded after the topical administration of one or both of the first and second crosslinkable entities.

13. The method according to claim 11 , wherein the microneedling is performed after the topical administration of one or both of the first and second crosslinkable entities. .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2021
From: MITRAGOTRI, SAMIR; SPENGLER, ERIC; LEVINSON, DOUGLAS; VOGUS, DOUGLAS R.
To: FOUNT BIO, INC.
Reel/Frame 057023/0654 →
Continuity (2)
Provisional Application 62754995 · Nov 2, 2018
Related Publication 20230165780A1 · Jun 1, 2023
References Cited (58)
US 8038991B1 · Stankus · 2011 [cited by examiner]
US 9932333B2 · Kanai et al. · 2018 [cited by applicant]
US 10624865B2 · Pathak · 2020 [cited by applicant]
US 20040127699A1 · Zhao et al. · 2004 [cited by applicant]
US 20060008428A1 · Seyler et al. · 2006 [cited by applicant]
US 20060159714A1 · Thorel · 2006 [cited by applicant]
US 20070142575A1 · Zheng · 2007 [cited by examiner]
US 20090156480A1 · Akashi et al. · 2009 [cited by applicant]
US 20110223625A1 · Kelts et al. · 2011 [cited by applicant]
US 20130096081A1 · Njikang et al. · 2013 [cited by applicant]
US 20130165463A1 · Gurtner · 2013 [cited by examiner]
US 20140227174A1 · Muraski et al. · 2014 [cited by applicant]
US 20140256831A1 · Ito et al. · 2014 [cited by applicant]
US 20170348218A1 · Chen et al. · 2017 [cited by applicant]
US 20180186900A1 · Mitragotri et al. · 2018 [cited by applicant]
US 20220175819A1 · Mitragotri et al. · 2022 [cited by applicant]
CA 3118491A1 · 2020 [cited by applicant]
CN 103097388A · 2013 [cited by applicant]
CN 105407920A · 2016 [cited by applicant]
CN 113365602A · 2021 [cited by applicant]
JP 2009519239A · 2009 [cited by applicant]
JP 2016106112A · 2016 [cited by applicant]
WO WO2007064773A2 · 2007 [cited by applicant]
WO WO2008016983A2 · 2008 [cited by applicant]
WO WO2009108100A1 · 2009 [cited by applicant]
WO WO2012010704A1 · 2012 [cited by applicant]
WO WO2013159064A1 · 2013 [cited by applicant]
WO WO2014057139A2 · 2014 [cited by applicant]
WO WO2014178878A1 · 2014 [cited by applicant]
WO WO2016010092A1 · 2016 [cited by applicant]
WO WO2016201382A1 · 2016 [cited by applicant]
WO WO2017173026A1 · 2017 [cited by applicant]
WO WO2020093022A1 · 2020 [cited by applicant]
WO WO2020214889A1 · 2020 [cited by applicant]
WO WO2022094002A1 · 2022 [cited by applicant]
International Search Report for PCT/US2021/056916, 5 pages (Feb. 8, 2022). [cited by applicant]
Written Opinion for PCT/US2021/056916, 9 pages (Feb. 8, 2022). [cited by applicant]
Bos, J. D. and Meinardi, M. M., The 500 Dalton rule for the skin penetration of chemical compounds and drugs, Experimental Dermatology, 9(3):165-169 (2000). [cited by applicant]
Doyle, G. and Mccutcheon, J., Development of an Open Source Educational Resource: “Clinical Procedures for Safer Patient Care”, Stud. Health Technol. Inform., 225:979-980 (2016). [cited by applicant]
Jinglong Cai et al., Scar Plastic and Aesthetic Surgery, Zhejiang Science and Technology Press, pp. 534-536 (2015). [cited by applicant]
Mcconville, A., et al., Mini-Review: Assessing the Potential Impact of Microneedle Technologies on Home Healthcare Applications, Medicines (Basel), 5(2):50 (2018). [cited by applicant]
Ruan, S., Ligand-Mediated and Enzyme-Directed Precise Targeting and Retention for the Enhanced Treatment of Glioblastoma, ACS Applied Materials& Inferfaces vol. 9, No. 24 (2017). [cited by applicant]
Ruel-Gariepy, E. and Leroux, J-C., In situ-forming hydrogels—review of temperature-sensitive systems, Eur J Pharm Biopharm, 58(2):409-26 (2004). [cited by applicant]
Seal, B. L., et al., Polymeric biomaterials for tissue and organ regeneration, Materials Science and Engineering, 34(4-5):147-230 (2001). [cited by applicant]
Srinivas, P. et al., Micro Needle Patches in Drug Delivery—A Review, International Journal of Pharmacy and Technology, 2(3):329-344 (2010). [cited by applicant]
Wang, Z. et al., Supplementary Material for Hierarchical Assembly of Bioactive Amphiphilic Molecule Pairs into Supramolecular Nanofibril Self-Supportive Scaffolds for Stem Cell Differentiation, XP055706252 (2016). [cited by applicant]
Dubikovskaya, E. et al., Precursor molecules for the synthesis of D-luciferin, WO2014057139A2, pp. 1-2 (2014). [cited by applicant]
International Search Report for PCT/US20/28639 (Delivery and Retention of Active Agents Within the Skin, filed Apr. 17, 2020), received by ISA/EP, 7 pages (Jul. 1, 2020). [cited by applicant]
International Search Report for PCT/US2019/059553 (Crosslinked Materials, filed Nov. 1, 2019), received from ISA/EP, 5 pages (Feb. 21, 2020). [cited by applicant]
Ng, K.W. and Lau, W.M., Skin Deep: The Basics of Human Skin Structure and Drug Penetration, N. Dragicevic, H.I. Maibach (eds.), [cited by applicant]
Ruan, S. et al., Ligand-Mediated and Enzyme-Directed Precise Targeting and Retention for the Enhanced Treatement of Glioblastoma, ACS Appl. Mater. Interfaces., 9:20348-20360 (2017). [cited by applicant]
Wang, P. et al., Site-specific immobilization of biomolecules by a biocompatable reaction between terminal cysteine and 2-cyanobenzothiazole, Chem. Commun., 49:8644-8646 (2013). [cited by applicant]
Wang, Z. et al., Hierarchical Assembly of Bioactive Amphiphilic Molecule Pairs into Supramolecular Nanofibril Self-Supportive Scaffolds for Stem Cell Differentiation, J. Am. Chem. Soc., 138:15027-15034 (2016). [cited by applicant]
Written Opinion for PCT/US20/28639 (Delivery and Retention of Active Agents Within the Skin, filed Apr. 17, 2020), received by ISA/EP, 10 pages (Jul. 1, 2020). [cited by applicant]
Written Opinion for PCT/US2019/059553 (Crosslinked Materials, filed Nov. 1, 2019), received from ISA/EP, 9 pages (Feb. 21, 2020). [cited by applicant]
Yuan, Y. et al., Intracellular Self-Assembly of Taxol Nanoparticles for Overcoming Multidrug Resistance, Angew. Chem. Int. Ed., 54:9700-9704 (215). [cited by applicant]
Zhang, X. et al., Improved method for synthesis of cysteine modified hyaluronic acid for in situ hydrogel formation, Chemical Communications, 51:9662-9665 (2015). [cited by applicant]
Casale, J. and Crane, J.S., Biochemistry, Glycosaminoglycans. [Updated Mar. 27, 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan. 2024-. Available from: https://www.ncbi.nlm.nih.gov/boo… [cited by applicant]
Cited By (1)
US 12,721,861